CoChat
Cited by 203

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

Open access
Hirode, Grishma, Choi, Hannah S.J., Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace, Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan, Sonneveld, Milan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, Kao, Jia-Horng, Cornberg, Markus, Hansen, Bettina E., Jeng, Wen-Juei, Janssen, Harry L.A. · 2022 · Gastroenterology

Abstract

BACKGROUND & AIMS: Functional cure, defined based on hepatitis B surface antigen (HBsAg) loss, is rare during nucleos(t)ide analogue (NA) therapy and guidelines on finite NA therapy have not been well established. We aim to analyze off-therapy outcomes after NA cessation in a large, international, multicenter, multiethnic cohort of patients with chronic hepatitis B (CHB). METHODS: This cohort study included patients with virally suppressed CHB who were hepatitis B e antigen (HBeAg)-negative and stopped NA therapy. Primary outcome was HBsAg loss after NA cessation, and secondary outcomes included virologic, biochemical, and clinical relapse, alanine aminotransferase flare, retreatment, and liver-related events after NA cessation. RESULTS: Among 1552 patients with CHB, cumulative probability of HBsAg loss was 3.2% at 12 months and 13.0% at 48 months of follow-up. HBsAg loss was higher among Whites (vs Asians: subdistribution hazard ratio, 6.8; 95% confidence interval, 2.7-16.8; P < .001) and among patients with HBsAg levels <100 IU/mL at end of therapy (vs ≥100 IU/mL: subdistribution hazard ratio, 22.5; 95% confidence interval, 13.1-38.7; P < .001). At 48 months of follow-up, Whites with HBsAg levels <1000 IU/mL and Asians with HBsAg levels <100 IU/mL at end of therapy had a high predicted probability of HBsAg loss (>30%). Incidence rate of hepatic decompensation and hepatocellular carcinoma was 0.48 per 1000 person-years and 0.29 per 1000 person-years, respectively. Death occurred in 7/19 decompensated patients and 2/14 patients with hepatocellular carcinoma. CONCLUSIONS: The best candidates for NA withdrawal are virally suppressed, HBeAg- negative, noncirrhotic patients with CHB with low HBsAg levels, particularly Whites with <1000 IU/mL and Asians with <100 IU/mL. However, strict surveillance is recommended to prevent deterioration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2021.11.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 203

Metadata

Authors
Hirode, G., Choi, H. S. J., Chen, C.-H., Su, T.-H., Seto, W.-K., Van Hees, S., Papatheodoridi, M., Lens, S., Wong, G., Brakenhoff, S. M., Chien, R.-N., Feld, J., Sonneveld, M. J., Chan, H. L. Y., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M.-F., Hsu, Y.-C., Kao, J.-H., Cornberg, M., Hansen, B. E., Jeng, W.-J., & Janssen, H. L. A.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2022-03
Volume
162
Issue
3
Pages
757-771.e4
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3211797588
Cited by
203
References
3
FWCI
18.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). https://app.cochat.ai/papers/10.1053/j.gastro.2021.11.002
The paper
Hirode, G., Choi, H. S. J., Chen, C.-H., Su, T.-H., Seto, W.-K., Van Hees, S., Papatheodoridi, M., Lens, S., Wong, G., Brakenhoff, S. M., Chien, R.-N., Feld, J., Sonneveld, M. J., Chan, H. L. Y., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M.-F., Hsu, Y.-C., . . . Janssen, H. L. A. (2022). Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology. https://doi.org/10.1053/j.gastro.2021.11.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.